Amoxicillin Tablets Rx
Generic Name and Formulations:
Amoxicillin (as trihydrate) 500mg, 875mg; tabs.
Various generic manufacturers
Indications for Amoxicillin Tablets:
Susceptible infections including ear/nose/throat (ENT), genitourinary tract, skin and skin structures, lower respiratory, acute uncomplicated gonorrhea.
>40kg: ENT: mild/moderate: 500mg every 12hrs; severe: 875mg every 12hrs. Lower respiratory tract: 875mg every 12hrs. Skin/skin structure: mild/moderate: 500mg every 12hrs; severe: 875mg every 12hrs. Genitourinary tract: mild/moderate: 500mg every 12hrs; severe: 875mg every 12hrs. Gonorrhea, acute uncomplicated ano-genital and urethral infections: 3g as single oral dose.
≤3 months: max 30mg/kg per day in 2 divided doses every 12hrs. >3 months (<40kg): ENT, genitourinary, skin: 25mg/kg/day in divided doses every 12hrs. Severe infections, or lower respiratory infections: 45mg/kg/day in divided doses every 12hrs. Gonorrhea: <2yrs: not recommended; prepubertal: amoxicillin 50mg/kg + probenecid 25mg/kg as a single dose.
Cephalosporin, imipenem or other allergy: not recommended. Monitor blood, renal, and hepatic function in long-term use. Labor & delivery. Pregnancy (Cat.B). Nursing mothers.
May cause false (+) glucose test with Clinitest, Benedict's or Fehling's soln. Serum levels increased by probenecid.
GI upset, hypersensitivity reactions (eg, urticaria, rash, Stevens-Johnson syndrome, anaphylaxis), hyperactivity, blood dyscrasias.
Formerly known under the brand names Amoxil, Trimox, Ultimox, Wymox (caps, susp), Polymox (susp).
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Canagliflozin Trial for T2D With CKD Stopped Early Due to Positive Results
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- Risk for Hypoglycemia During Titration With Insulin Glargine 100 U/mL in T2D
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Effect of SGLT2 Inhibitors on Heart Failure-Related Hospitalization, Below-Knee Amputation
- Nutraceuticals Containing Equol May Be Effective for Postmenopausal Symptoms
- Conservative Monitoring Strategy for Non-Functioning Pituitary Adenomas Evaluated
- FDA: Some Rx Drugs May Become Available Without Seeing a Doctor
- PM2.5 Contributes to Burden of Diabetes Mellitus Globally